SEC For	m 4 FORM	4		STATE	es se	-		-		NGE C	оммі	SSION				
				Washington, D.C. 20549								OMB APPROVAL				
Section 16. Form 4 or Form 5 obligations may continue. See					Pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							Estimated a		lumber: ted average burde per response:	3235-0287 en 0.5	
1. Name and Address of Reporting Person <sup>*</sup> Nanavaty Maulik					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Rani Therapeutics Holdings, Inc.</u> [ RANI ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O RANI THERAPEUTICS LLC					3. Date of Earliest Transaction (Month/Day/Year) 05/25/2022							Officer below)	(give title	e title Other (specify below)		
2051 RINGWOOD AVE.				4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) SAN JOSE CA 95131												X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)													
		Tab	ole I - Non-E	Derivati	ve Se	curities	s Ac	quired, D	isposed o	of, or Be	neficial	ly Owned				
Date				Transacti ate Ionth/Day/	Execution Date			e, Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		Beneficia Owned F	s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	t Beneficial Ownership	
								Code V	Amount	(A) or (D)	Price	Price Reported Transaction (Instr. 3 and			(Instr. 4)	
		-	Table II - De (e.					uired, Dis , options				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	e, 4. Code	saction e (Instr.	5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	y Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				Code	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to	\$10.89	05/25/2022		A		41,416		(1)	05/24/2032	Class A Common Stock	41,416	\$0.00	41,416	D		

## Explanation of Responses:

1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).

## Remarks:

/s/ Svai Sanford, Attorney-in-						
Fact for Maulik Nanavaty	<u>05</u>					

05/27/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.